Repare Therapeutics
| General Information | |
| Business: |
We are a leading precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Synthetic lethality, or SL, represents a clinically validated approach to drug development. We use our proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. SL arises when a deficiency in either of two genes is tolerated in cells, but simultaneous deficiencies in both genes cause cell death. |
| Industry: | PHARMACEUTICAL PREPARATIONS |
| Employees: | 64 |
| Founded: | 2016 |
| Contact Information | |
| Address | 7210 Frederick-Banting, Suite 100, Montréal, Québec, Canada H4S 2A1, |
| Phone Number | (857) 412-7018 |
| Web Address | http://www.reparerx.com |
| View Prospectus: | Repare Therapeutics |
| Financial Information | |
| Market Cap | $700.4mil |
| Revenues | $0 mil (last 12 months) |
| Net Income | $-34.98 mil (last 12 months) |
| IPO Profile | |
| Symbol | RPTX |
| Exchange | NASDAQ |
| Shares (millions): | 11.0 |
| Price range | $20.00 - $20.00 |
| Est. $ Volume | $220.0 mil |
| Manager / Joint Managers | Morgan Stanley/ Goldman Sachs/ Cowen and Company/ Piper Sandler |
| CO-Managers | - |
| Expected To Trade: | 6/19/2020 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |